Tipifarnib in Treating Patients With Recurrent Bladder Cancer

NCT00047216 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

OTHER

Sponsor class

Conditions

Bladder Cancer

Interventions

DRUG: tipifarnib

Sponsor

University Health Network, Toronto

Collaborators

[object Object]